PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Genitourinary Cancer

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort

Prostate

Shimomura T, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group

doi: 10.1002/pros.24898

Genitourinary Cancer

Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial

J Urol

Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, Agarwal N, Spratt DE

doi: 10.1097/JU.0000000000004158

Genitourinary Cancer

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Eur Urol Oncol

Wallis CJD, Ekberg S, Morgans AK, Boegemann M, Paracha N, Gallagher E, Crowther MJ, Shore N

doi: 10.1016/j.euo.2025.03.001

ASCO 2024

Genitourinary Cancer

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

Genitourinary Cancer

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

JAMA Oncol

Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F

doi: 10.1001/jamaoncol.2024.0591

ASCO 2024

Genitourinary Cancer

Real-world study: Apalutamide achieved improved deep, early PSA response versus enzalutamide in patients with de novo mHSPC

Genitourinary Cancer

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review

BJU Int

Raval AD, Chen S, Littleton N, Constantinovici N, Goebell PJ

doi: 10.1111/bju.16577

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Gastrointestinal Cancer

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Int J Cancer

van Nassau SCMW, Zwart K, van der Baan FH, Vink GR, Elferink MAG, Snaebjornsson P, May AM, Koopman M, Roodhart JML

doi: 10.1002/ijc.35410

Related content

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort

Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

Real-world study: Apalutamide achieved improved deep, early PSA response versus enzalutamide in patients with de novo mHSPC

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort